2025
Evaluating the Effect of Epigallocatechin Gallate (EGCG) in Reducing Folate Levels in Reproductive Aged Women by MTHFR and DHFR Genotype in Combination With Letrozole or Clomiphene
Johnson J, Siblini H, Al‐Hendy A, Segars J, González F, Taylor H, Singh B, Carson S, Christman G, Huang H, Dangi B, Zhang H. Evaluating the Effect of Epigallocatechin Gallate (EGCG) in Reducing Folate Levels in Reproductive Aged Women by MTHFR and DHFR Genotype in Combination With Letrozole or Clomiphene. Clinical And Translational Science 2025, 18: e70189. PMID: 40077973, PMCID: PMC11903501, DOI: 10.1111/cts.70189.Peer-Reviewed Original ResearchConceptsEpigallocatechin-3-gallateFolate levelsUterine fibroidsClinical trialsGreen tea extractAssociated with folate deficiencyPresence of MTHFRWomen of Childbearing AgeSerum folate levelsReduced folate levelsActive clinical trialsReproductive-age womenEffect of epigallocatechin gallateDHFR genotypeDHFR polymorphismTea extractDaily doseClomiphene citrateUnexplained infertilityFolate deficiencyChildbearing ageClinical studiesTreated womenFibroidsLetrozole
2024
Fibroids and unexplained infertility treatment with epigallocatechin gallate: a natural compound in green tea (FRIEND) – protocol for a randomised placebo-controlled US multicentre clinical trial of EGCG to improve fertility in women with uterine fibroids
Al-Hendy A, Segars J, Taylor H, González F, Siblini H, Zamah M, Alkelani H, Singh B, Flores V, Christman G, Johnson J, Huang H, Zhang H. Fibroids and unexplained infertility treatment with epigallocatechin gallate: a natural compound in green tea (FRIEND) – protocol for a randomised placebo-controlled US multicentre clinical trial of EGCG to improve fertility in women with uterine fibroids. BMJ Open 2024, 14: e078989. PMID: 38216200, PMCID: PMC10806662, DOI: 10.1136/bmjopen-2023-078989.Peer-Reviewed Original ResearchConceptsUnexplained infertilityIntrauterine inseminationInstitutional review boardCumulative live birth rateUterine fibroidsLive birth rateCause of infertilityFood and Drug AdminstrationGonadotropin hormone-releasing hormoneGreen tea extractDouble-blind clinical trialNon-surgical treatment optionsTimed intrauterine inseminationUterine fibroid sizeOvarian stimulationQuality of Life Questionnaire scoresHormone-releasing hormoneLocal institutional review boardInfertility treatmentNational Institute of Child HealthInstitute of Child HealthMiscarriage rateBirth rateReproductive-age womenEndometrial quality
2023
Assessing the Hepatic Safety of Epigallocatechin Gallate (EGCG) in Reproductive-Aged Women
Siblini H, Al-Hendy A, Segars J, González F, Taylor H, Singh B, Flaminia A, Flores V, Christman G, Huang H, Johnson J, Zhang H. Assessing the Hepatic Safety of Epigallocatechin Gallate (EGCG) in Reproductive-Aged Women. Nutrients 2023, 15: 320. PMID: 36678191, PMCID: PMC9861948, DOI: 10.3390/nu15020320.Peer-Reviewed Original ResearchConceptsReproductive-aged womenLiver function testsUterine fibroidsUnexplained infertilityClomiphene citrateSerum liver function testsEpigallocatechin gallateSigns of drugSerum folate levelsGreen tea catechinsHepatic safetyPremenopausal womenProspective cohortDaily doseLiver injuryFunction testsTreatment armsLiver toxicityClinical studiesCommon causeFolate levelsEarly safety assessmentInterim analysisNormal rangeUse of EGCG
2022
Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials
Donnez J, Taylor HS, Stewart EA, Bradley L, Marsh E, Archer D, Al-Hendy A, Petraglia F, Watts N, Gotteland JP, Bestel E, Terrill P, Loumaye E, Humberstone A, Garner E. Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials. The Lancet 2022, 400: 896-907. PMID: 36116480, DOI: 10.1016/s0140-6736(22)01475-1.Peer-Reviewed Original ResearchConceptsHeavy menstrual bleedingPhase 3 trialSymptomatic uterine fibroidsMenstrual bleedingUterine fibroidsTherapy groupPlacebo groupOral gonadotropin-releasing hormone receptor antagonistResponse rateGonadotropin-releasing hormone receptor antagonistCommon adverse eventsFull analysis setHormone receptor antagonistDose of treatmentMasked treatmentPrimary endpointStudy drugAdverse eventsEligible womenHot flushesChronic treatmentReceptor antagonistGonadal steroidsLinzagolixAnalysis set
2020
Menstruation: science and society
Critchley HOD, Babayev E, Bulun SE, Clark S, Garcia-Grau I, Gregersen PK, Kilcoyne A, Kim JJ, Lavender M, Marsh EE, Matteson KA, Maybin JA, Metz CN, Moreno I, Silk K, Sommer M, Simon C, Tariyal R, Taylor HS, Wagner GP, Griffith LG. Menstruation: science and society. American Journal Of Obstetrics And Gynecology 2020, 223: 624-664. PMID: 32707266, PMCID: PMC7661839, DOI: 10.1016/j.ajog.2020.06.004.Peer-Reviewed Original ResearchMeSH KeywordsAdenomyosisAttitudeBiological EvolutionBiomedical ResearchCongresses as TopicDeveloping CountriesEducationEndometriosisEndometriumFemaleGlobal HealthHealth LiteracyHumansLeiomyomaMenstrual Hygiene ProductsMenstruationMenstruation DisturbancesMesenchymal Stem CellsMicrobiotaMicrofluidic Analytical TechniquesNational Institute of Child Health and Human Development (U.S.)RegenerationStem CellsTerminology as TopicTissue EngineeringUnited StatesUterine HemorrhageUterine NeoplasmsUterusWomen's HealthConceptsAbnormal uterine bleedingMenstruation-related disordersUterine bleedingEunice Kennedy Shriver National InstituteHealth concernScarless healing processWomen's health concernsMenstrual healthGynecologic healthUterine preservationMiddle-income countriesProgesterone withdrawalVascular functionClinical challengeHigh-income countriesEndometrial biologyChild healthHealth literacyMost womenHealthy individualsMenstrual physiologyOverall healthReproductive healthDisease BranchMenstruationCXCL12 Attracts Bone Marrow-Derived Cells to Uterine Leiomyomas
Moridi I, Mamillapalli R, Kodaman PH, Habata S, Dang T, Taylor HS. CXCL12 Attracts Bone Marrow-Derived Cells to Uterine Leiomyomas. Reproductive Sciences 2020, 27: 1724-1730. PMID: 32020550, DOI: 10.1007/s43032-020-00166-x.Peer-Reviewed Original ResearchConceptsBone marrow-derived cellsMarrow-derived cellsExpression of CXCL12Uterine leiomyomaLeiomyoma growthCommon benign gynecologic tumorsNormal myometriumEngraftment of BMDCsBenign gynecologic tumorsCXCR4 antagonist AMD3100Myometrium of womenStem/progenitor cellsUterine myomaGynecologic tumorsMyoma cellsAntagonist AMD3100CXCR4 expressionControl myometriumReproductive ageUterine diseaseMouse uterusCurrent evidenceLeiomyomaBone marrowMyometrium
2019
H19 lncRNA identified as a master regulator of genes that drive uterine leiomyomas
Cao T, Jiang Y, Wang Z, Zhang N, Al-Hendy A, Mamillapalli R, Kallen AN, Kodaman P, Taylor HS, Li D, Huang Y. H19 lncRNA identified as a master regulator of genes that drive uterine leiomyomas. Oncogene 2019, 38: 5356-5366. PMID: 31089260, PMCID: PMC6755985, DOI: 10.1038/s41388-019-0808-4.Peer-Reviewed Original ResearchConceptsSingle nucleotide polymorphismsKey pathway genesGenome-scale studiesGenome-wide transcriptomeExtracellular matrixMethylation profiling analysisRegulation of expressionKey driver genesH19 single nucleotide polymorphismsEpigenetic modificationsMaster regulatorPathway genesTET expressionExpression changesExpression of H19H19 lncRNADriver genesProfiling analysisGenesH19Smooth muscle cellsUnifying mechanismMuscle cellsNovel target therapiesLncRNAs
2018
Uterine stem cells: from basic research to advanced cell therapies
Santamaria X, Mas A, Cervelló I, Taylor H, Simon C. Uterine stem cells: from basic research to advanced cell therapies. Human Reproduction Update 2018, 24: 673-693. PMID: 30239705, DOI: 10.1093/humupd/dmy028.Peer-Reviewed Original ResearchConceptsBone marrow-derived stem cellsMyometrial stem cellsAtrophic endometriumAsherman's syndromeUterine pathologyCell therapyStem cellsMarrow-derived stem cellsNovel therapeutic approachesTumor-initiating cellsStem/progenitor cellsStem cell therapyUterine stem cellsUterine transplantationHuman endometriumUterine physiologyUterine leiomyomaTherapeutic approachesMouse modelHuman uterusAdvanced stem cell therapyAnimal modelsBone marrowEndometriumAutologous sourceFibroids: when should they be removed to improve in vitro fertilization success?
Taylor HS. Fibroids: when should they be removed to improve in vitro fertilization success? Fertility And Sterility 2018, 109: 784-785. PMID: 29778372, DOI: 10.1016/j.fertnstert.2018.03.003.Peer-Reviewed Original Research
2017
Current and Emerging Medical Treatments for Uterine Fibroids
Chwalisz K, Taylor H. Current and Emerging Medical Treatments for Uterine Fibroids. Seminars In Reproductive Medicine 2017, 35: 510-522. PMID: 29100239, DOI: 10.1055/s-0037-1606302.Peer-Reviewed Original ResearchMeSH KeywordsCombined Modality TherapyCost of IllnessDrug ApprovalDrugs, InvestigationalEvidence-Based MedicineFemaleGonadotropin-Releasing HormoneHormone AntagonistsHumansLeiomyomaLeiomyomatosisMenorrhagiaQuality of LifeReceptors, ProgesteroneUnited StatesUnited States Food and Drug AdministrationUterine NeoplasmsConceptsUterine fibroidsMedical therapyMedical treatmentOral gonadotropin-releasing hormone antagonistLong-term medical therapyGonadotropin-releasing hormone antagonistCommon uterine neoplasmPressure-related symptomsHeavy menstrual bleedingProgesterone receptor modulatorsRandomized clinical trialsSymptomatic uterine fibroidsUnited States FoodMenstrual bleedingUterine neoplasmsSymptom managementSurgical interventionHormone antagonistClinical trialsReceptor modulatorsMedical optionsEffective treatmentClinical developmentFibroidsDrug Administration
2015
Infertility and reproductive disorders: impact of hormonal and inflammatory mechanisms on pregnancy outcome
Vannuccini S, Clifton VL, Fraser IS, Taylor HS, Critchley H, Giudice LC, Petraglia F. Infertility and reproductive disorders: impact of hormonal and inflammatory mechanisms on pregnancy outcome. Human Reproduction Update 2015, 22: 104-115. PMID: 26395640, PMCID: PMC7289323, DOI: 10.1093/humupd/dmv044.Peer-Reviewed Original ResearchConceptsPoor pregnancy outcomesPregnancy outcomesObstetric complicationsReproductive disordersHormonal aberrationsPreventative care measuresFetal growth restrictionAdvanced maternal ageEvidence-based recommendationsDecidual senescenceHypertensive disordersPerinatal outcomesUnexplained infertilityInflammatory mechanismsPreterm birthPlacental pathologyInflammatory pathwaysMaternal ageVascular abnormalitiesCare measuresCare pathwayClinical managementGrowth restrictionAffected patientsMetabolic factorsLeiomyoma-derived transforming growth factor-β impairs bone morphogenetic protein-2-mediated endometrial receptivity
Doherty LF, Taylor HS. Leiomyoma-derived transforming growth factor-β impairs bone morphogenetic protein-2-mediated endometrial receptivity. Fertility And Sterility 2015, 103: 845-852. PMID: 25596622, PMCID: PMC4363085, DOI: 10.1016/j.fertnstert.2014.12.099.Peer-Reviewed Original ResearchConceptsEndometrial stromal cellsLeukemia inhibitory factorEndometrial receptivityTGF receptorElevated TGF-β levelsCultured endometrial stromal cellsTGF-β receptor type IITGF-β antibodyTGF-β levelsReceptor type 1aReceptor type IIBMP receptor type 1AEnzyme-linked immunosorbentRecombinant human BMP-2LIF expressionSymptomatic leiomyomasPregnancy lossSurgical specimensPretreatment levelsUterine leiomyomaReceptor type 1BMAIN OUTCOMELeiomyoma cellsLeiomyomaHuman BMP-2
2014
Uterine Fibroids: Clinical Manifestations and Contemporary Management
Doherty L, Mutlu L, Sinclair D, Taylor H. Uterine Fibroids: Clinical Manifestations and Contemporary Management. Reproductive Sciences 2014, 21: 1067-1092. PMID: 24819877, DOI: 10.1177/1933719114533728.Peer-Reviewed Original ResearchConceptsMedical therapyUterine fibroidsGrowth factorAbnormal uterine bleedingHeavy menstrual bleedingInterventional radiological proceduresEndometrial effectsUterine bleedingMenstrual bleedingMedical managementSurgical managementCommon lesionsCurrent armamentariumFibroid treatmentClinical trialsEffective treatmentFibroidsRadiological proceduresDrug AdministrationFibroid cellsNovel therapeuticsAbnormal regulationTherapyFibroid biologyMolecular changesMicroRNA and gynecological reproductive diseases
Santamaria X, Taylor H. MicroRNA and gynecological reproductive diseases. Fertility And Sterility 2014, 101: 1545-1551. PMID: 24882618, DOI: 10.1016/j.fertnstert.2014.04.044.Peer-Reviewed Original ResearchConceptsSmall non-coding RNAsTranslation of mRNAsNon-coding RNAsAberrant miRNA expressionHuman diseasesMiRNA expressionAbnormal expressionMicroRNAsReproductive tract diseaseReproductive diseasesExpressionGenesMiRNAsMiRNARNATranslationMRNATherapeutic toolDysregulationGynecological diseasesInflammatory diseases
2010
Leiomyoma Simultaneously Impair Endometrial BMP-2-Mediated Decidualization and Anticoagulant Expression through Secretion of TGF-β3
Sinclair DC, Mastroyannis A, Taylor HS. Leiomyoma Simultaneously Impair Endometrial BMP-2-Mediated Decidualization and Anticoagulant Expression through Secretion of TGF-β3. The Journal Of Clinical Endocrinology & Metabolism 2010, 96: 412-421. PMID: 21084396, PMCID: PMC3048319, DOI: 10.1210/jc.2010-1450.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntithrombin IIIBlood CoagulationBone Morphogenetic Protein 2Cells, CulturedDeciduaDNA, ComplementaryEnzyme-Linked Immunosorbent AssayFemaleHumansImmunohistochemistryInfertility, FemaleLeiomyomaMenorrhagiaMiddle AgedPlasminogen Activator Inhibitor 1Reverse Transcriptase Polymerase Chain ReactionRNAStromal CellsThrombomodulinTransforming Growth Factor beta3Uterine NeoplasmsConceptsEndometrial stromal cellsAntithrombin IIIPAI-1Bone morphogenetic protein receptorTGF-β3Primary endometrial stromal cellsEffects of leiomyomaReproductive-age womenPlasminogen activator inhibitor-1Expression of HOXA10TGF-β3 treatmentEndometrial gene expressionUniversity Medical CenterLess PAI-1Activator inhibitor-1Endometrial defectQuantitative RT-PCREndometrial decidualizationMenstrual bleedingLIF expressionMiscarriage riskUterine leiomyomaMedical CenterReproductive dysfunctionCase control
2008
Submucosal uterine leiomyomas have a global effect on molecular determinants of endometrial receptivity
Rackow BW, Taylor HS. Submucosal uterine leiomyomas have a global effect on molecular determinants of endometrial receptivity. Fertility And Sterility 2008, 93: 2027-2034. PMID: 18555231, PMCID: PMC3107853, DOI: 10.1016/j.fertnstert.2008.03.029.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkers, TumorCase-Control StudiesEmbryo ImplantationEndometriumFemaleGene Expression Regulation, NeoplasticHomeobox A10 ProteinsHomeodomain ProteinsHumansInfertility, FemaleKruppel-Like Transcription FactorsLeiomyomaLeukemia Inhibitory FactorMiddle AgedMucous MembranePrognosisUterine NeoplasmsConceptsReal-time reverse transcriptase-polymerase chain reactionSubmucosal myomasEndometrial receptivityUterine leiomyomaMRNA expressionEndometrial HOXA10 expressionSubmucosal uterine leiomyomasLIF mRNA expressionReproductive-aged womenTime of surgeryCase-control studyReverse transcriptase-polymerase chain reactionHOXA10 protein expressionQuantitative real-time reverse transcriptase-polymerase chain reactionUniversity Medical CenterTranscriptase-polymerase chain reactionMessenger RNA expressionReal-time RT-PCREndometrial samplingPrimary endpointEndometrial biopsyUterine myomaIntramural myomasMedical CenterReproductive dysfunction
2002
Coordinated regulation of HOX gene expression in myometrium and uterine leiomyoma
Cermik D, Arici A, Taylor HS. Coordinated regulation of HOX gene expression in myometrium and uterine leiomyoma. Fertility And Sterility 2002, 78: 979-984. PMID: 12413981, DOI: 10.1016/s0015-0282(02)03366-6.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply